Amylin: The Pancreatic Hormone Emerging as a Powerful Obesity and Diabetes Treatment
Long-acting amylin analogs like cagrilintide produce substantial weight loss, and combining them with GLP-1 drugs achieves synergistic effects exceeding 15% body weight reduction.
Quick Facts
What This Study Found
Cagrilintide combined with GLP-1 receptor agonists achieves synergistic weight loss exceeding 15%, positioning amylin analogs as key players in diabesity treatment.
Key Numbers
How They Did This
Narrative review of preclinical and clinical studies on amylin physiology and analog development over the past five years.
Why This Research Matters
Obesity and diabetes together (diabesity) are a growing global epidemic. Amylin analogs offer a new hormonal pathway to complement GLP-1 drugs, potentially achieving weight loss and glucose control that neither achieves alone.
The Bigger Picture
The combination of amylin and GLP-1 pathways represents the next frontier in metabolic medicine, moving beyond single-hormone approaches toward multi-target therapies for obesity and diabetes.
What This Study Doesn't Tell Us
Review article without new primary data. Long-term safety and durability of amylin analog effects still need confirmation from large phase 3 trials.
Questions This Raises
- ?Will cagrilintide plus semaglutide (CagriSema) maintain its weight loss advantage in large phase 3 trials?
- ?What is the long-term cardiovascular safety profile of amylin-GLP-1 combinations?
- ?Can amylin analogs benefit patients who have plateaued on GLP-1 monotherapy?
Trust & Context
- Key Stat:
- >15% weight loss Amylin analog + GLP-1 RA combination therapy for diabesity in clinical studies
- Evidence Grade:
- Narrative review covering a mix of preclinical data and early clinical trials; cagrilintide results are promising but from smaller studies.
- Study Age:
- Published in 2026, reviewing advances from 2021–2026.
- Original Title:
- Amylin Revisited: A 5-Year Perspective on Its Emerging Role in the Treatment of Diabesity.
- Published In:
- Journal of obesity & metabolic syndrome, 35(1), 38-48 (2026)
- Authors:
- Chung, Chae Won, Kim, Jaetaek
- Database ID:
- RPEP-15043
Evidence Hierarchy
Frequently Asked Questions
What is amylin and how is it different from GLP-1?
Amylin is a hormone co-released with insulin from the pancreas. While GLP-1 drugs mimic a gut hormone to boost insulin and reduce appetite, amylin works through different brain pathways to promote fullness and slow stomach emptying—combining both covers more biological pathways.
Is cagrilintide available yet?
Cagrilintide is in advanced clinical trials, often combined with semaglutide as CagriSema. It is not yet FDA-approved but may become available pending successful phase 3 results.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-15043APA
Chung, Chae Won; Kim, Jaetaek. (2026). Amylin Revisited: A 5-Year Perspective on Its Emerging Role in the Treatment of Diabesity.. Journal of obesity & metabolic syndrome, 35(1), 38-48. https://doi.org/10.7570/jomes25085
MLA
Chung, Chae Won, et al. "Amylin Revisited: A 5-Year Perspective on Its Emerging Role in the Treatment of Diabesity.." Journal of obesity & metabolic syndrome, 2026. https://doi.org/10.7570/jomes25085
RethinkPeptides
RethinkPeptides Research Database. "Amylin Revisited: A 5-Year Perspective on Its Emerging Role ..." RPEP-15043. Retrieved from https://rethinkpeptides.com/research/chung-2026-amylin-revisited-a-5year
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.